Clearside Biomedical Inc (NASDAQ:CLSD) has been assigned an average recommendation of “Buy” from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $21.25.
A number of equities analysts have recently commented on the company. Zacks Investment Research raised Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Friday. Cowen reaffirmed a “buy” rating on shares of Clearside Biomedical in a report on Wednesday, October 25th.
In related news, Director Clay Thorp sold 5,000 shares of the stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $6.13, for a total value of $30,650.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Daniel H. White sold 8,000 shares of the stock in a transaction on Thursday, October 19th. The stock was sold at an average price of $7.82, for a total value of $62,560.00. Following the completion of the sale, the insider now owns 477,935 shares in the company, valued at approximately $3,737,451.70. The disclosure for this sale can be found here. Insiders sold 152,000 shares of company stock valued at $1,132,035 over the last ninety days. Corporate insiders own 20.90% of the company’s stock.
Several hedge funds have recently modified their holdings of CLSD. Bank of New York Mellon Corp raised its position in shares of Clearside Biomedical by 10.8% in the first quarter. Bank of New York Mellon Corp now owns 34,823 shares of the company’s stock worth $277,000 after buying an additional 3,404 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Clearside Biomedical by 30.7% in the first quarter. TIAA CREF Investment Management LLC now owns 19,257 shares of the company’s stock worth $153,000 after buying an additional 4,527 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Clearside Biomedical in the first quarter worth $604,000. Goldman Sachs Group Inc. raised its position in shares of Clearside Biomedical by 33.4% in the first quarter. Goldman Sachs Group Inc. now owns 43,852 shares of the company’s stock worth $348,000 after buying an additional 10,972 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its position in shares of Clearside Biomedical by 175.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 38,600 shares of the company’s stock worth $352,000 after buying an additional 24,600 shares in the last quarter. Institutional investors own 51.73% of the company’s stock.
Shares of Clearside Biomedical (CLSD) traded down $0.31 during midday trading on Thursday, reaching $5.89. The company’s stock had a trading volume of 149,295 shares, compared to its average volume of 118,029. Clearside Biomedical has a 1-year low of $5.44 and a 1-year high of $10.46. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.57 and a quick ratio of 4.57.
Clearside Biomedical (NASDAQ:CLSD) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.17). Clearside Biomedical had a negative net margin of 17,684.07% and a negative return on equity of 90.72%. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.01 million. analysts anticipate that Clearside Biomedical will post -2.37 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Clearside Biomedical Inc (CLSD) Receives $21.25 Consensus PT from Brokerages” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/11/clearside-biomedical-inc-clsd-receives-21-25-consensus-pt-from-brokerages.html.
About Clearside Biomedical
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc and related companies with MarketBeat.com's FREE daily email newsletter.